SWOG clinical trial number
SWOG-9221 (MDACC, ID91-025) (INT-I91-0001)

Phase III Double-Blind Randomized Trial of 13-Cis Retinoic Acid (13-cRA) to Prevent Second Primary Tumors (SPTs) in Stage I Non-Small Cell Lung Cancer

Closed
Phase
Published
Abbreviated Title
Phase III Double-Blind Randomized Trial of 13-Cis Retinoic Acid (13-cRA) to Prevent Second Primary Tumors (SPTs) in Stage I Non-Small Cell Lung Cancer
Activated
03/15/1993
Closed
04/09/1997

Research committees

Lung Cancer

Publication Information Expand/Collapse

2001

Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer.

SM Lippman;JJ Lee;DD Karp;EE Vokes;SE Benner;GE Goodman;FR Khuri;R Marks;RJ Winn;W Fry;SL Graziano;DR Gandara;G Okawara;CL Woodhouse;B Williams;C Perez;HW Kim;R Lotan;JA Roth;WK Hong Journal of the National Cancer Institute 93(8):605-618

1998

Phase III intergroup trial of 13-cis-retinoic acid to prevent second primary tumors in stage-I non-small cell lung cancer (NSCLC): Interim report of NCI #191-0001.

SM Lippman;JJ Lee;DD Karp;EE Vokes;SE Benner;GE Goodman;C Kardinal;RJ Winn;JA Roth;WK Hong Proc of the American Society of Clinical Oncology 17:456a(#1753)

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/A082304/S2402

Perioperative Versus Adjuvant Systemic Therapy In Patients with Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG, CTIU2317
Research Committee(s)
Lung Cancer
Activated
12/11/2024
Open